# A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations

> **NCT07472907** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cilcare SAS** · enrollment: 135 (estimated)

## Conditions studied

- Cochlear Synaptopathy

## Interventions

- **DRUG:** CIL001 (Paliroden)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07472907
- **Lead sponsor:** Cilcare SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-07
- **Final completion:** 2027-12
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472907, "A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07472907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*